2020 COLLECTION TYPE: MEDICARE PART B CLAIMS

MEASURE TYPE: Process

DESCRIPTION: The percentage of women age 50-85 who suffered a fracture in the six months prior to the performance period through June 30 of the performance period and who either had a bone mineral density test or received a prescription for a drug to treat osteoporosis in the six months after the fracture

INSTRUCTIONS: This measure is to be submitted after each occurrence of a fracture during the six months prior to the performance period through June 30 of the performance period. It is anticipated that Merit-based Incentive Payment System (MIPS) eligible clinicians who treat any fracture except fractures of the finger, toe, face or skull will submit this measure. Each occurrence of a fracture is identified by either an ICD-10-CM diagnosis code for fracture and a CPT service code OR an ICD-10-CM diagnosis code for a fracture and a CPT procedure code for surgical treatment of fractures.

NOTE: Patients with any fracture except fractures of the finger, toe, face or skull should have a bone mineral density (BMD) measurement performed or pharmacologic therapy prescribed. The management (BMD performed or pharmacologic therapy prescribed) should occur within six months of the fracture. If multiple fractures occurring on the same date of service are submitted on the same claim form, only one instance of submission will be counted. Claims data will be analyzed to determine unique occurrences. Patients already receiving pharmacologic therapy would automatically meet the intent of this measure.

Measure Submission Type: Measure data may be submitted by individual MIPS eligible clinicians using Medicare Part B claims. The listed denominator criteria are used to identify the intended patient population. The numerator quality-data codes included in this specification are used to submit the quality actions allowed by the measure on the claim form(s). All measure-specific coding should be submitted on the claim(s) representing the denominator eligible encounter and selected numerator option.

The intent of the exclusion for individuals age 66 and older residing long-term care facilities, including nursing homes, is to exclude individuals who may have limited life expectancy and increased frailty where the benefit of the process may not exceed the risks. This exclusion is not intended as a clinical recommendation regarding whether the measures process is inappropriate for specific populations, instead the exclusions allows clinicians to engage in shared decision making with patients about the benefits and risks of screening when an individual has limited life expectancy.

DENOMINATOR: Women who experienced a fracture, except fractures of the finger, toe, face or skull, during the six months prior to the performance period through June 30 of the performance period

Option 1 - Denominator Criteria (Eligible Cases):
Patients aged 50-85 years on date of encounter
Patients aged 50-85 years on date of encounter

AND

Option 2 - Denominator Criteria (Eligible Cases):
Patients aged 50-85 years on date of encounter

AND

Diagnosis for any fracture except fractures of the finger, toe, face or skull (ICD-10-CM):
AND

Patient procedure during the performance period (CPT): 22310, 22315, 22318, 22319, 22325, 22326, 22327, 22510, 22511, 22513, 22514, 25600, 25605, 25606, 25607, 25608, 27230, 27232, 27235, 27236, 27238, 27240, 27244, 27245, 27246, 27248

NUMERATOR:
Patients who received either a bone mineral density test or a prescription for a drug to treat osteoporosis in the six months after the fracture

Definitions:
Pharmacologic Therapy – U.S. Food and Drug Administration approved pharmacologic options for osteoporosis prevention and/or treatment of postmenopausal osteoporosis include: bisphosphonates, alendronate, alendronate-cholecalciferol, ibandronate, risedronate, zoledronic acid, calcitonin, teriparatide, denosumab, and raloxifine.

Prescribed – May include prescription given to the patient for treatment of osteoporosis (as listed above) at one or more encounters during the performance period, or documentation that patient is already taking pharmacologic therapy for osteoporosis, as documented in the current medical list.

Bone Mineral Density (BMD) – A bone density test is an examination by either special x-rays or ultrasound to determine how much bone mineral content (calcium and other minerals) is present in any section of bone.

NUMERATOR NOTE: While the Central Dual Energy X-Ray Absorptiometry (DXA) is the most common measurement for measuring bone mineral density (BMD), for the purposes of submitting this measure, spinal densitometry X-ray, ultrasonography for densitometry, CT bone density axial and Peripheral Dual-energy X-Ray Absorptiometry (DXA) would meet performance and the intent of the measure and 3095F would be submitted.
Numerator Quality-Data Coding Options:
Patient receiving Hospice Services, Patient Not Eligible:

Denominator Exclusion: G9768: Patients who utilize hospice services any time during the measurement period

OR

Bone Mineral Density Measurement Results not Documented for Medical Reasons

Denominator Exclusion: G9769: Patient had a bone mineral density test in the past two years OR received osteoporosis medication or therapy in the past 12 months

OR

Patient age 66 or older in Institutional SNP or residing in long-term care facility, Patient Not Eligible

Denominator Exclusion: G9938: Exclude all encounters from the denominator for patients age 66 and older in Institutional Special Needs Plans (SNP) or residing in long term care with POS code 32, 33, 34, 54 or 56 for more than 90 days during the measurement period

OR

G2126: Patient 66 years of age and older and had at least one claim/encounter for frailty during the measurement period AND either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ED or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period

OR

G2127: Patients 66 years of age and older and had at least one claim/encounter for frailty during the measurement period AND a dispensed dementia medication

Table: Dementia Exclusion Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinesterase inhibitors</td>
<td>Donepezil</td>
</tr>
<tr>
<td></td>
<td>Galantamine</td>
</tr>
<tr>
<td>Miscellaneous central nervous system agents</td>
<td>Memantine</td>
</tr>
</tbody>
</table>

OR

Bone Mineral Density Measurement Ordered or Results Documented or Pharmacologic Therapy Prescribed

Performance Met: CPT II 3095F: Central Dual-energy X-Ray Absorptiometry (DXA) results documented

OR

Performance Met: G8633: Pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed

OR

Bone Mineral Density Measurement Results not Documented, Reason not Otherwise Specified

Append a submission modifier (8P) to CPT Category II code 3095F to submit circumstances when the action described in the numerator is not performed and the reason is not otherwise specified.

Performance Not Met: 3095F with 8P: Central Dual-energy X-Ray Absorptiometry (DXA) measurement was not performed, reason not otherwise
Pharmacologic Therapy not Prescribed, Reason not Given

Performance Not Met: G8635: Pharmacologic therapy for osteoporosis was not prescribed, reason not given

RATIONALE:
The intent of this measure is secondary prevention of fractures through the appropriate diagnosis and treatment of osteoporosis. Detecting osteoporosis and initiating treatment will help to prevent future fractures from occurring.

Future fractures, especially in the older population, can cause significant health issues, decline in function, and, in some cases lead to mortality.

CLINICAL RECOMMENDATION STATEMENTS:
Appropriate follow-up care for a fracture in post-menopausal women includes either 1) bone mineral density testing to assess whether a patient has osteoporosis or 2) receiving pharmacologic therapy to treat osteoporosis. This measure is based on guidelines and evidence that patients at high risk of fracture, including patients with a history of fragility fractures, should be screened for osteoporosis (USPSTF 2012, Nelson 2010, AACE 2010) and that patients who have a fragility fracture of the hip or spine should be provided with a treatment for osteoporosis (AACE 2010, Crandall 2012).

“The USPSTF recommends screening for osteoporosis in women aged 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors” (USPSTF 2011).

All postmenopausal women with a history of fracture without major trauma should receive a bone mineral density test to test for osteoporosis (AACE 2010). Patients who have a history of fracture of the hip or spine also need pharmacologic therapy to treat for osteoporosis (AACE 2010; NOF 2014).


COPYRIGHT:
Physician Performance Measures (Measures) and related data specifications have been developed by the PCPI® Foundation (PCPI®) and the National Committee for Quality Assurance (NCQA). These Measures are not a clinical guideline and do not establish a standard of medical care, and has not been tested for all potential applications. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the PCPI® or NCQA. Neither the American Medical Association (AMA), nor the former AMA-convened Physician Consortium for Performance Improvement(R), PCPI, NCQA nor its members shall be responsible for any use of the Measure. © 2019 NCQA and PCPI® Foundation. All Rights Reserved.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.

2020 Medicare Part B Claims Flow for Quality ID #418: NQF #0053: Osteoporosis Management in Women Who Had a Fracture: Option 1

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.

Multiple Performance

Denominator

- Patient Aged 50-85 Years on Date of Encounter
  - No
  - Yes
    - Diagnosis Any Fracture as Listed in Denominator
      - No
        - Not included in Eligible Population/Denominator
          - Yes
            - Denominator Exclusion G9768 (10 episodes) \( x^1 \)
          - No
            - Denominator Exclusion G9708 (10 episodes) \( x^2 \)
      - Yes
        - Encounter as Listed in Denominator (1/1/2020 thru 12/31/2020) Option 1\(^a\)
          - Yes
            - Include in Eligible Population/Denominator (100 episodes)
          - No
            - Numerator

Numerator

- Data Completeness Met + Denominator Exclusion G9768 (10 episodes) \( x^1 \)
  - Yes
    - Patients Who Utilize Hospice Services Any Time During the Measurement Period
      - No
        - Data Completeness Met + Denominator Exclusion G9708 (10 episodes) \( x^2 \)
      - Yes
        - Denominator Exclusion G9835 (6 episodes) \( x^1 \)
  - No
    - Data Completeness Met + Denominator Exclusion G9835 (6 episodes) \( x^1 \)
      - Yes
        - Data Completeness Met + Performance Met 3065F with BP (20 episodes) \( a^4 \)
      - No
        - Data Completeness Met + Performance Met 3065F (20 episodes) \( a^2 \)

- Data Completeness Met + Performance Met 3065F (20 episodes) \( a^2 \)
  - Yes
    - Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Specified
      - No
        - Data Completeness Met + Performance Not Met 3065F with BP (20 episodes) \( a^4 \)
      - Yes
        - Bone Mineral Density Test OR Received Osteoporosis Medication or Therapy
          - No
            - Data Completeness Met + Performance Not Met 3065F with BP (20 episodes) \( a^4 \)
          - Yes
            - Pharmacologic Therapy for Osteoporosis Was Not Prescribed, Reason Not Given
              - No
                - Patients aged 65 and older in Institutional Special Needs Plans (SNP) or residing in long-term care with POS code 32, 33, 34, 54, or 50 for more than 30 days during the measurement period
                  - Yes
                    - Data Completeness Met + Performance Not Met 3065F with BP (20 episodes) \( a^4 \)
              - Yes
                - Data Completeness Met + Performance Not Met 3065F with BP (20 episodes) \( a^4 \)

- Patient 65 and older with 2+ claims/Encounter for Frailty AND Either 1 Acute Illness Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis
  - Yes
    - Data Completeness Met + Denominator Exclusion G2128 (0 episodes) \( x^1 \)
  - No
    - Data Completeness Met + Denominator Exclusion G2127 (0 episodes) \( x^2 \)

- Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented
  - Yes
    - Pharmacologic Therapy (Other Than Minerals/Vitamins) OR Osteoporosis Prescribed
      - No
        - Data Completeness Met + Performance Met 3065F (20 episodes) \( a^2 \)
      - Yes
        - Data Completeness Met + Performance Not Met 3065F with BP (20 episodes) \( a^4 \)
  - No
    - Data Completeness Met + Performance Not Met 3065F (20 episodes) \( a^2 \)
SAMPLE CALCULATIONS:

Data Completeness:

\[
\text{Denominator Exclusion (x thru x^2 = 40 episodes) + Performance Met (x^2 + x^2 + x^2 = 80 episodes) + Performance Not Met (x^2 + x^2 + x^2 = 50 episodes)} = 190 \text{ episodes} = 90.00\%
\]

\[
\text{Eligible Population} / \text{Denominator (x^2 + x^2 = 200 episodes)} = 200 \text{ episodes}
\]

Performance Rate:

\[
\text{Performance Met (x^2 + x^2 + x^2 = 80 episodes)} = 80 \text{ episodes} = 57.14\%
\]

\[
\text{Data Completeness Numerator (180 episodes) - Denominator Exclusion (x thru x^2 = 40 episodes)} = 140 \text{ episodes}
\]

* See the posted measure specification for specific coding and instructions to submit this measure.

**While the Central Dual Energy X-Ray Absorptiometry (DXA) is the most common measurement for measuring bone mineral density (BMD), for the purposes of submitting this measure, spinal densitometry, X-ray, ultrasonography for densitometry, CT bone density axial and Peripheral Dual-energy X-Ray Absorptiometry (DXA) would meet performance and the intent of the measure and 50S5F would be submitted.

This measure contains 2 Submission Criteria, although as the Sample Calculation indicates, there is ONLY one data completeness and one performance rate for this measure.

NOTE: Submission Frequency: Episode
2020 Medicare Part B Claims Flow Narrative for Quality ID #418 NQF #0053: 
Osteoporosis Management in Women Who Had a Fracture

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.

Option 1:

1. Start with Denominator
2. Check Patient Age:
   a. If Patient Aged 50 to 85 Years on Date of Encounter equals No during the measurement period, do not include in Eligible Population. Stop Processing.
   b. If Patient Aged 50 to 85 Years on Date of Encounter equals Yes during the measurement period, proceed to check Patient Diagnosis.
3. Check Patient Diagnosis:
   a. If Diagnosis of Any Fracture as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Diagnosis of Any Fracture as Listed in the Denominator equals Yes, proceed to check Encounter Performed.
4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator Option 1 equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator Option 1 equals Yes, include in Eligible Population.
5. Denominator Population:
   a. Denominator Population is all Eligible Episodes in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d1 equals 100 episodes in the Sample Calculation.
6. Start Numerator
7. Check Patients Who Utilize Hospice Services Any Time During the Measurement Period:
   a. If Patients Who Utilize Hospice Services Any Time During the Measurement Period equals Yes, include in Data Completeness Met and Denominator Exclusion.
   b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter x1 equals 10 episodes in the Sample Calculation.
   c. If Patients Who Utilize Hospice Services Any Time During the Measurement Period equals No, proceed to check Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months.
8. Check Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months:
a. If Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months equals Yes, include in Data Completeness Met and Denominator Exclusion.

b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter x² equals 10 episodes in the Sample Calculation.

c. If Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months equals No, proceed to check Patients Aged 66 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 for more than 90 days during the measurement period.

9. Check Patients Aged 66 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 for more than 90 days during the measurement period

a. If Patients Aged 66 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 for more than 90 days during the measurement period equals Yes, include in Data Completeness Met and Denominator Exclusion.

b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter x³ equals 0 episodes in the Sample Calculation.

c. If Patients Aged 66 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 for more than 90 days during the measurement period equals No, proceed to check Patient 66 years of age and older with ≥ 1 Claim/Encounter for Frailty AND Either 1 Acute Inpatient Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis.

10. Check Patient 66 years of age and older with greater than or equal to 1 Claim/Encounter for Frailty AND Either 1 Acute Inpatient Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis:

a. If Patient 66 years of age and older with greater than or equal to 1 Claim/Encounter for Frailty AND Either 1 Acute Inpatient Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis equals No, proceed to check Patients Aged ≥ 81 Years with Evidence of Frailty equals Yes, include in Data Completeness Met and Denominator Exclusion.

b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter x⁴ equals 0 episodes in the Sample Calculation.

c. If Patient 66 years of age and older with greater than or equal to 1 Claim/Encounter for Frailty AND Either 1 Acute Inpatient Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis equals No, proceed to check Patients 66 years of age and older with one or more Claim/Encounter for Frailty AND Dispensed Medication for Dementia.

11. Check Patients 66 years of age and older with one or more Claim/Encounter for Frailty AND Dispensed Medication for Dementia:

a. If Patients 66 years of age and older with one or more Claim/Encounter for Frailty AND Dispensed Medication for Dementia equals Yes, include in Data Completeness Met and Denominator Exclusion.

b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter x⁵ equals 0 episodes in the Sample Calculation.
the Sample Calculation.

c. If Patients 66 years of age and older with one or more Claim/Encounter for Frailty AND Dispensed Medication for Dementia equals No, proceed to check Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented**.

12. Check Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented**:
   a. If Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented** equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a¹ equals 20 episodes in the Sample Calculation.
   c. If Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented** equals No, proceed to check Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed.

13. Check Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed:
   a. If Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a² equals 20 episodes in the Sample Calculation.
   c. If Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed equals No, proceed to check Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement was Not Performed, Reason Not Otherwise Specified.

14. Check Central Dual-energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified:
   a. If Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified equals Yes, include in Data Completeness Met and Performance Not Met.
   b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c¹ equals 20 episodes in the Sample Calculation.
   c. If Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified equals No, proceed to check Pharmacologic Therapy (other than minerals/vitamins) for Osteoporosis was Not Prescribed, Reason Not Given.

15. Check Pharmacologic Therapy for Osteoporosis was Not Prescribed, Reason Not Given:
   a. If Pharmacologic Therapy for Osteoporosis was Not Prescribed, Reason Not Given equals Yes, include in Data Completeness Met and Performance Not Met.
   b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c² equals 10 episodes in the Sample Calculation.
   c. If Pharmacologic Therapy for Osteoporosis was Not Prescribed, Reason Not Given equals No, proceed to check Data Completeness Not Met.
16. Check Data Completeness Not Met:

   a. If Data Completeness Not Met, the Quality Data Code was not submitted. 10 episodes have been subtracted from the Data Completeness Numerator in the Sample Calculation.
Option 2:

1. Start with Denominator

2. Check Patient Age:
   a. If Patients Aged 50 to 85 Years on Date of Encounter equals No during the measurement period, do not include in Eligible Population. Stop Processing.
   b. If Patients Aged is 50 to 85 Years on Date of Encounter equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of Any Fracture as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Diagnosis of Any Fracture as Listed in the Denominator equals Yes, proceed to check Procedure Performed.

4. Check Procedure Performed:
   a. If Procedure as Listed in the Denominator Option 2 equals No, do not include in Eligible Population. Stop Processing.
   b. If Procedure as Listed in the Denominator Option 2 equals Yes, include in Eligible Population.

5. Denominator Population:
   a. Denominator Population is all Eligible Episodes in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter $d$ equals 100 episodes in the Sample Calculation.

6. Start Numerator

7. Check Patients Who Utilize Hospice Services Any Time During the Measurement Period:
   a. If Patients Who Utilize Hospice Services Any Time During the Measurement Period equals Yes, include in Data Completeness Met and Denominator Exclusion.
   b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter $x$ equals 10 episodes in the Sample Calculation.
   c. If Patients Who Utilize Hospice Services Any Time During the Measurement Period equals No, proceed to check Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months.

8. Check Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months:
a. If Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months equals Yes, include in Data Completeness Met and Denominator Exclusion.

b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter \( x^7 \) equals 10 episodes in the Sample Calculation.

c. If Patient had a Bone Mineral Density Test in the Past Two Years OR Received Osteoporosis Medication or Therapy in the Past 12 Months equals No, proceed to check Patients Aged 66 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 for more than 90 days during the measurement period.

9. Check Patients Aged 66 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 for more than 90 days during the measurement period

a. If Patients Aged 66 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 for more than 90 days during the measurement period equals Yes, include in Data Completeness Met and Denominator Exclusion.

b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter \( x^8 \) equals 0 episodes in the Sample Calculation.

c. If Patients Aged 66 or Older in Institutional Special Needs Plans (SNP) or Residing in Long-Term Care with POS code 32, 33, 34, 54, or 56 for more than 90 days during the measurement period equals No, proceed to check Patients 66 years of age and older with greater than or equal to 1 Claim/Encounter for Frailty AND Either 1 Acute Inpatient Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis.

10. Check Patients 66 years of age and older with greater than or equal to 1 Claim/Encounter for Frailty AND Either 1 Acute Inpatient Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis:

a. If Patients 66 years of age and older with greater than or equal to 1 Claim/Encounter for Frailty AND Either 1 Acute Inpatient Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis equals Yes, include in Data Completeness Met and Denominator Exclusion.

b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter \( x^9 \) equals 0 episodes in the Sample Calculation.

c. If Patients 66 years of age and older with greater than or equal to 1 Claim/Encounter for Frailty AND Either 1 Acute Inpatient Encounter or 2 Outpatient, Observation, ED or Nonacute Inpatient Encounters with Advanced Illness Diagnosis equals No, proceed to check Patients 66 years of age and older with one or more Claim/Encounter for Frailty AND Dispensed Medication for Dementia.

11. Check Patients 66 years of age and older with one or more Claim/Encounter for Frailty AND Dispensed Medication for Dementia:

a. If Patients 66 years of age and older with one or more Claim/Encounter for Frailty AND Dispensed Medication for Dementia equals Yes, include in Data Completeness Met and Denominator Exclusion.

b. Data Completeness Met and Denominator Exclusion letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter \( x^{10} \) equals 0 episodes in the Sample Calculation.
c. If Patients 66 years of age and older with one or more Claim/Encounter for Frailty AND Dispensed Medication for Dementia equals No, proceed to check Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented.

12. Check Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented:
   a. If Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a³ equals 20 episodes in the Sample Calculation.
   c. If Central Dual-Energy X-Ray Absorptiometry (DXA) Results Documented equals No, proceed to check Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed.

13. Check Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed:
   a. If Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a⁴ equals 20 episodes in Sample Calculation.
   c. If Pharmacological Therapy (Other Than Minerals/Vitamins) for Osteoporosis Prescribed equals No, proceed to check Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified.

14. Check Central Dual-energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified:
   a. If Central Dual-Energy X-Ray Absorptiometry (DXA) Measurement Was Not Performed, Reason Not Otherwise Specified equals Yes, include in Data Completeness Met and Performance Not Met.
   b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c³ equals 20 episodes in the Sample Calculation.

15. Check Pharmacologic Therapy for Osteoporosis was Not Prescribed, Reason Not Given:
   a. If Pharmacologic Therapy for Osteoporosis was Not Prescribed, Reason Not Given equals Yes, include in Data Completeness Met and Performance Not Met.
   b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c⁴ equals 10 episodes in the Sample Calculation.
   c. If Pharmacologic Therapy for Osteoporosis was Not Prescribed, Reason Not Given equals No, proceed to check Data Completeness Not Met.
16. Check Data Completeness Not Met:
   
a. If Data Completeness Not Met, the Quality Data Code was not submitted. 10 episodes have been subtracted from the Data Completeness Numerator in Sample Calculation.

   **SAMPLE CALCULATIONS:**
   
   Data Completeness:
   \[
   \text{Denominator Exclusion (x^* = 40 episodes)} + \text{Performance Metric (x^* = 60 episodes)} + \text{Performance Not Met (x^* = 120 episodes)} = 380 \text{ episodes} = 95.00\
   \text{Eligible Population / Denominator (x^* = 400 episodes)} = 200 \text{ episodes}
   \]
   
   Performance Rate:
   \[
   \frac{\text{Performance Not Met (x^* = 40 episodes)}}{\text{Data Completeness Numerator (140 episodes) - Denominator Exclusion (x^* = 40 episodes)}} = 30 \text{ episodes} = 67.14\
   \]
   
   Data Completeness Numerator (140 episodes) = 140 episodes